A Phase 4 interventional study of Regimen:BIC+FTC+TAF in HIV Infection and HIV, sponsored by National Center for AIDS/STD Control and Prevention, China CDC. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-17.
Sponsored by National Center for AIDS/STD Control and Prevention, China CDC · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in HIV Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. HIV Infections · China.
Among the 67 studies in HIV Infections with a site in China, this one is the 18th largest by planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 in phase 4, and was the 62nd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →10 of the 67 studies in HIV Infections with a site in China are open now. Recruiting first, the newest first:
Liaoning Chengda Biotechnology CO., LTD · Sites in China
Ages 18–60
Jecho Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18–65
Shanghai Public Health Clinical Center · Sites in China
Ages 18+
Chinese University of Hong Kong · Sites in China
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 5 · Phase 3 11 · Phase 4 14
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 145 across the 50 interventional studies, 435 across the 16 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 67 have an industry lead sponsor. The 10 most frequent:
National Center for AIDS/STD Control and Prevention, China CDC is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
National Center for AIDS/STD Control and Prevention, China CDC has 4 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06830668National Center for AIDS/STD Control and Prevention, China CDCSame-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation | 2026-12-31 |
| NCT07579741Jecho Biopharmaceuticals Co., Ltd.A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders | 2027-02-12 |
| NCT07932132Liaoning Chengda Biotechnology CO., LTDImmunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 67 studies in HIV Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In China, free first-line ART regimens typically consist of two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI). As of the end of 2022, approximately 1.135 million individuals were receiving ART, achieving a coverage rate of 92.8%, largely due to participation in free treatment programs. However, around 36,000 patients have discontinued treatment, primarily due to side effects associated with Efavirenz (EFV), a common NNRTI. The challenges posed by side effects and resistance profiles of existing NNRTIs highlight the need for effective re-initiation of ART to improve overall treatment coverage. INSTIs, particularly B/F/TAF (Bictegravir/emtricitabine/tenofovir alafenamide), demonstrates effective viral suppression and a higher barrier to resistance than NNRTIs. B/F/TAF has shown efficacy in patients with resistance mutations, making it a strong candidate for same-day ART re-initiation, especially in resource-limited areas where genotypic resistance testing may be unavailable. This study aims to evaluate the feasibility and effectiveness of rapidly restarting B/F/TAF in patients with treatment interruptions from previous NNRTI regimens.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
••Patients who are pregnant.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV patients of any gender, older than 18 years of age, who have been off their prior NNRTI regimen for more than 90 days and who have an HIV-1 viral load greater than 50 copies/uL.In this study, eligible patients will restart treatment on the same day and receive B/F/TAF for one year.We will conduct follow-ups on the patients and carry out routine clinical tests.
Drug: Regimen:BIC+FTC+TAF
Same-day restart of "BIC+FTC+TAF" among HIV patients who experienced discontinuation from previous NNRTI-based regimens
The efficacy of re-initiation of B/F/TAF
Evaluate the efficacy following the re-initiation of B/F/TAF as determined by the achievement of HIV-RNA undetectable (\< 50 copies/ml).
Time frame: From enrollment to the end of treatment at 24 weeks
Drug resistance status
Describe drug resistance status
Time frame: From enrollment to the end of treatment at 48 weeks
The reasons for discontinuation of prior therapy
Describe the reasons for discontinuation of prior therapy
Time frame: From enrollment to the end of treatment at 1 week
The efficacy of B/F/TAF
Evaluate the efficacy of B/F/TAF (achievement of HIV-1 RNA\< 50 copies/ml and HIV-1 RNA \< 200 copies/ml) among those participants rapidly restarting B/F/TAF
Time frame: From enrollment to the end of treatment at Week 12, Week24 and Week 48
The persistence on B/F/TAF .
Evaluate the persistence on B/F/TAF during the study period and describe the reasons for discontinuation of B/F/TAF if it happens.
Time frame: From enrollment to the end of treatment at 48 weeks
The changes in parameters of quality of life and treatment satisfaction
Describe changes in parameters of quality of life and treatment satisfaction
Time frame: From enrollment to the end of treatment at Week24 and Week 48
The safety and tolerability on B/F/TAF
Evaluate the safety and tolerability on B/F/TAF during the study period.
Time frame: From enrollment to the end of treatment at 48 weeks
The emergence of drug resistance
Describe the emergence of drug resistance developed during the study period.
Time frame: From enrollment to the end of treatment at 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2025; primary completion for Dec 2026, 22 months later.
Of 78 non-industry phase 4 interventional studies under HIV Infections, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 45. This study's planned 22 months is below that.
Counting every sponsor, half of 91 studies reached it within 35 months; a quarter within 23 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Center for AIDS/STD Control and Prevention, China CDC